Orion Oyj (OTCMKTS:ORINY) Stock Price Down 0.9% – Should You Sell?

Orion Oyj (OTCMKTS:ORINY) shares were down 0.9% during trading on Tuesday . The company traded as low as $23.36 and last traded at $23.36. Approximately 151 shares changed hands during trading, a decline of 69% from the average daily volume of 488 shares. The stock had previously closed at $23.57.

Orion Oyj Price Performance

The company has a market capitalization of $6.59 billion, a price-to-earnings ratio of 18.54 and a beta of 0.22. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.39 and a quick ratio of 1.29. The business has a fifty day moving average price of $25.46 and a 200 day moving average price of $23.67.

Orion Oyj (OTCMKTS:ORINY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.63 EPS for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The company had revenue of $517.97 million for the quarter. On average, research analysts expect that Orion Oyj will post 1.26 earnings per share for the current fiscal year.

Orion Oyj Cuts Dividend

The business also recently disclosed a dividend, which was paid on Thursday, November 7th. Investors of record on Wednesday, October 16th were issued a $0.2405 dividend. The ex-dividend date was Wednesday, October 16th. Orion Oyj’s dividend payout ratio is presently 26.98%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.